TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Abstract

Chronic airway obstruction drives progressive respiratory failure, necessitating highly targeted pharmacological interventions. This clinical investigation evaluates the comparative efficacy of phenotype-guided inhalation regimens in stabilizing pulmonary function and mitigating exacerbations among patients with advanced airflow limitation. In a prospective, randomized 18-month clinical trial, 342 adults diagnosed with moderate-to-severe obstructive pulmonary pathology were monitored using spirometry, peripheral blood eosinophil quantification, and the COPD Assessment Test. Empirical data dictates that untargeted bronchodilation strategies yield suboptimal outcomes in patients exhibiting active systemic eosinophilic inflammation. By stratifying the cohort and deploying a precise triple therapy regimen (long-acting muscarinic antagonist + long-acting beta2-agonist + inhaled corticosteroid) specifically in patients with elevated eosinophil counts (>= 300 cells/microL), the experimental protocol achieved profound functional stabilization. Statistical modeling demonstrates this phenotype-directed approach reduced the annualized rate of moderate-to-severe exacerbations by 46.8% while securing a sustained improvement in forced expiratory volume in one second (FEV1) by 142 +/- 18 mL over baseline (p < 0.001). The transition from generic bronchodilator escalation to biomarker-driven therapeutic algorithms provides a mathematically verified paradigm advancement, offering a highly accurate, non-invasive blueprint capable of preserving ventilatory mechanics in high-risk demographics.